Social anxiety sits at the center of this dementia and brain health question.
If your doctor diagnosed social anxiety disorder and handed you a prescription for an SSRI, you received the standard playbook. But standard does not mean best, and for the estimated 15 to 20 million American adults living with social anxiety disorder in any given year, SSRIs fail or fall short for a significant number of them. What few patients hear is that one of the most effective medications ever studied for social anxiety, phenelzine, has been available for decades. Six double-blind, placebo-controlled trials have consistently demonstrated its efficacy, and no treatment has been shown to be superior to it. Yet most psychiatrists never bring it up. Beyond phenelzine, there is an entire landscape of medications and investigational compounds that rarely make it into the fifteen-minute med check conversation. These include benzodiazepines with surprisingly strong response data, anticonvulsants that work through entirely different brain pathways, a therapy-boosting amino acid derivative, and even a nasal spray designed to calm the amygdala through chemosensory neurons.
Some of these are available now by prescription. Others are working through clinical trials with potential FDA decisions in the next year or two. This article walks through each option with the actual clinical data behind it, including where the evidence is strong, where it falls apart, and what the real-world tradeoffs look like for people who need more than sertraline can offer. Social anxiety disorder is not a niche condition. Lifetime prevalence sits between 12.1 and 13.3 percent of Americans, and over 75 percent of people with the disorder first showed symptoms during childhood or adolescence. Females have a higher past-year prevalence at 8.0 percent compared to 6.1 percent for males. For a condition this widespread and this early-onset, the narrow prescribing habits around it deserve scrutiny.
Table of Contents
- Why Do So Few Doctors Discuss Social Anxiety Drugs Beyond SSRIs?
- The MAOI That Outperforms Everything Else
- Clonazepam and the Benzodiazepine Question
- Pregabalin and Gabapentin as Alternative Pathways
- Beta-Blockers — The Popular Recommendation That May Not Hold Up
- D-Cycloserine and the Science of Enhancing Therapy
- Investigational Treatments on the Horizon
- Conclusion
- Frequently Asked Questions
Why Do So Few Doctors Discuss Social Anxiety Drugs Beyond SSRIs?
The short answer is liability, convenience, and training inertia. SSRIs and SNRIs became the default first-line treatment for social anxiety disorder in the early 2000s because they carry a relatively mild side effect profile, no abuse potential, and no dietary restrictions. For a busy prescriber seeing thirty patients a day, writing for sertraline or paroxetine is the path of least resistance. Phenelzine, the monoamine oxidase inhibitor that has outperformed or matched every other medication in head-to-head SAD trials, requires patients to follow a strict low-tyramine diet. Aged cheeses, cured meats, fermented foods, and certain beers are off limits. Failure to comply risks hypertensive crisis, a sudden and dangerous spike in blood pressure. That risk, combined with serious drug-drug interactions, makes most physicians avoid it entirely. But avoidance is not the same as informed decision-making.
A patient who has failed two SSRIs, tried an SNRI, and still cannot attend a work meeting without overwhelming dread deserves to know that phenelzine exists and that its track record is unmatched. A 2010 study published in JAMA Psychiatry found that combining phenelzine with cognitive behavioral group therapy was superior to either treatment alone. That finding matters enormously for treatment-resistant patients. The dietary restrictions are real, but they are also manageable for motivated individuals who understand the rules. The problem is that most patients never get the chance to weigh those tradeoffs because the conversation never happens. The same pattern holds for other options. Clonazepam has robust trial data for social anxiety but gets lumped into the “benzodiazepines are bad” narrative without nuance. Pregabalin is approved for generalized anxiety disorder in Europe but remains off-label and largely unknown for SAD in the United States. The result is a treatment funnel that pushes nearly everyone toward the same two or three medications, regardless of whether those medications are working.
The MAOI That Outperforms Everything Else
Phenelzine, sold under the brand name Nardil, occupies a strange position in psychiatry. It is FDA-approved for social anxiety disorder, panic disorder, and treatment-resistant depression. Its efficacy data for SAD is arguably the strongest of any single medication. And yet it accounts for a vanishingly small percentage of prescriptions written for social anxiety in the United States. The reason is almost entirely about the tyramine interaction. When someone taking an MAOI consumes foods high in tyramine, the enzyme that normally breaks down tyramine is blocked, allowing it to accumulate and trigger a potentially life-threatening spike in blood pressure. However, if a patient is organized, understands the dietary list, and can reliably avoid the restricted foods, phenelzine becomes a viable and powerful option. The restricted foods are specific and learnable. Fresh meats, most fresh cheeses, most vegetables, and most breads are fine.
The danger foods, like aged cheddar, salami, sauerkraut, and certain tap beers, are avoidable with planning. The bigger practical barrier is drug interactions. Phenelzine cannot be combined with SSRIs, most decongestants, certain pain medications, and a long list of other compounds. Switching from an SSRI to phenelzine requires a washout period of at least two weeks, and up to five weeks for fluoxetine. This makes the transition logistically complex and requires a prescriber who is comfortable managing it. The clinical payoff, though, is substantial. Across six controlled trials, phenelzine has consistently separated from placebo with large effect sizes. For someone who has cycled through multiple first-line medications without adequate relief, this is not a fringe option. It is a well-studied, FDA-approved treatment that happens to require more patient education and monitoring than most doctors want to take on.
Clonazepam and the Benzodiazepine Question
Benzodiazepines carry significant baggage in modern psychiatry, and much of that baggage is earned. But the clinical data for clonazepam in social anxiety disorder is difficult to dismiss. In the best-studied trial, clonazepam produced a 78.3 percent response rate compared to 20 percent for placebo. A longer-term study averaging 11.3 months of treatment found that 84.6 percent of participants showed good improvement. These are numbers that most SSRIs cannot match in SAD-specific trials. Clonazepam also has a somewhat more favorable side effect profile compared to other benzodiazepines used for anxiety. One comparison found side effect incidence of 26.7 percent for clonazepam versus 48.4 percent for alprazolam and 43.9 percent for lorazepam.
Its longer half-life means more stable blood levels throughout the day, which translates to fewer interdose withdrawal symptoms and less of the clock-watching that short-acting benzodiazepines can produce. The limitations are serious and well-documented. Dependence develops with regular use, sometimes within weeks. Discontinuation can be protracted and deeply uncomfortable, with rebound anxiety that often exceeds the original symptoms. The American Journal of Psychiatry’s 2014 review emphasized the risks of dependence, abuse potential, and worsening depression. Clonazepam is contraindicated for patients with a history of substance use disorder. For someone with comorbid alcohol problems or a history of opioid use, this option is off the table. But for a carefully selected patient, particularly someone with severe SAD who has failed other treatments and has no substance use history, clonazepam’s data warrants an honest discussion rather than reflexive dismissal.
Pregabalin and Gabapentin as Alternative Pathways
Pregabalin and gabapentin work through a mechanism entirely different from SSRIs, MAOIs, or benzodiazepines. They bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. For social anxiety disorder, this means calming the nervous system through a pathway that does not directly involve serotonin or GABA receptors. Pregabalin at 600 milligrams per day showed significant reduction in Liebowitz Social Anxiety Scale scores compared to placebo, with measurable improvement beginning by the first week of treatment. Its anxiolytic response rates at 450 to 600 milligrams daily are comparable to those seen with SSRIs and SNRIs. Gabapentin also showed significant improvement in SAD symptoms in a 14-week placebo-controlled trial, but required doses above 2,100 milligrams per day to achieve meaningful results. That is a high dose that means taking multiple pills throughout the day and dealing with side effects like sedation and dizziness.
Both medications are off-label for social anxiety in the United States. Pregabalin is approved for generalized anxiety disorder in Europe but the FDA has not granted that indication domestically, and neither drug has an SAD-specific approval anywhere. The tradeoff compared to SSRIs is instructive. Pregabalin tends to work faster, sometimes within days rather than the four to six weeks SSRIs typically require. It does not cause the sexual dysfunction that plagues SSRI use. But it can cause weight gain, cognitive dulling, and at higher doses, peripheral edema. Both pregabalin and gabapentin have shown usefulness as add-on therapy to SSRIs or CBT, which means they do not necessarily require abandoning a partially effective SSRI regimen. For patients who get some benefit from their current medication but not enough, adding pregabalin may close the gap without starting from scratch.
Beta-Blockers — The Popular Recommendation That May Not Hold Up
Propranolol for performance anxiety is one of the most commonly repeated pieces of medical folk wisdom in anxiety treatment. Musicians, public speakers, and test-takers have been using beta-blockers off-label for decades to manage the physical symptoms of anxiety: trembling hands, racing heart, shaky voice. But the evidence base for this practice is weaker than most people assume, and for generalized social anxiety disorder, it may not work at all. A 2024 systematic review and meta-analysis published in the Journal of Affective Disorders found no significant benefit of beta-blockers over placebo or benzodiazepines for social anxiety disorder or panic disorder. The 2014 Canadian anxiety guidelines similarly do not recommend propranolol for SAD based on controlled study evidence. All beta-blocker use for anxiety is off-label, and the gap between anecdotal enthusiasm and clinical trial results is wide.
This does not mean propranolol is useless in every situation. For narrow, predictable performance situations, like giving a quarterly presentation or playing a concert, some individuals report meaningful relief from the physical manifestations of anxiety. The shaking stops, the heart slows, the voice steadies. But beta-blockers do nothing for the cognitive and emotional dimensions of social anxiety: the anticipatory dread, the post-event rumination, the pervasive belief that others are judging you. For someone whose social anxiety extends beyond specific performances into everyday interactions, meetings, phone calls, and casual conversations, propranolol is unlikely to move the needle. The warning here is straightforward: do not mistake a popular recommendation for an evidence-based one.
D-Cycloserine and the Science of Enhancing Therapy
One of the more intellectually interesting approaches to social anxiety treatment does not involve taking a daily medication at all. D-cycloserine is a partial NMDA receptor agonist, originally developed as an antibiotic for tuberculosis, that has been studied as a way to enhance the learning that happens during exposure therapy. The idea is elegant: if social anxiety partly involves a failure to learn that feared social situations are actually safe, then boosting the brain’s learning machinery during therapeutic exposures could accelerate recovery. An initial randomized controlled trial with 27 participants found that taking d-cycloserine before exposure therapy sessions produced significantly less social anxiety afterward compared to placebo plus exposure.
But when a larger multisite study with 169 participants tested whether d-cycloserine could augment a full course of CBT for SAD, it did not show a benefit. Subsequent research suggested that the effectiveness of d-cycloserine appears conditional on whether the individual exposure sessions are actually successful. If a patient’s exposure goes well and anxiety decreases during the session, d-cycloserine enhances that learning. If the exposure goes poorly, the drug may actually reinforce the negative experience. This makes d-cycloserine a precision tool rather than a blanket enhancement, one that requires skilled therapy and careful session management to use effectively.
Investigational Treatments on the Horizon
Several compounds currently in clinical development could reshape social anxiety treatment within the next few years. Fasedienol, also known as PH94B, is a novel pherine nasal spray that activates nasal chemosensory neurons connected directly to the limbic amygdala. It has received FDA Fast Track designation for acute treatment of social anxiety disorder. In the PALISADE-2 Phase 3 trial, fasedienol reduced mean SUDS scores by 13.8 points compared to 8.0 points for placebo. However, the subsequent PALISADE-3 Phase 3 trial did not meet its primary or secondary endpoints. As of March 2026, fasedienol remains in clinical development and is not yet FDA-approved. The mixed Phase 3 results make its regulatory path uncertain.
Further out, psychedelic-assisted therapies are generating clinical data that would have been unthinkable a decade ago. MindMed is developing MM-120, a precise-dose form of LSD, for generalized anxiety disorder. A Phase 2 study showed that participants reported improvement after a single dose, with benefits observed for up to 12 weeks. If Phase 3 trials succeed, a potential FDA pathway could open in 2026 to 2027. Compass Pathways is conducting two Phase 3 trials of psilocybin for treatment-resistant depression with anxiety comorbidity, and one study showed 58 percent depression remission at the 12-month mark. New Mexico passed the Medical Psilocybin Act in 2025, establishing a regulated therapeutic program. No SAD-specific Phase 3 trials exist yet for psilocybin, but anxiety is measured as a secondary outcome in several ongoing depression trials. These are not treatments anyone can access today, but they represent a genuine expansion of what may be available within the next few years.
Conclusion
The landscape of social anxiety treatment extends far beyond SSRIs, but accessing it requires knowing what to ask for and finding a prescriber willing to venture past first-line defaults. Phenelzine remains the most effective medication studied for social anxiety disorder, held back primarily by dietary restrictions and prescriber discomfort rather than efficacy concerns. Clonazepam offers strong response rates but demands careful patient selection and honest conversations about dependence. Pregabalin provides an alternative mechanism with faster onset and no sexual side effects.
Beta-blockers, despite their popularity, lack evidence for generalized social anxiety and should not be treated as a reliable option beyond narrow performance situations. For patients who have not responded adequately to SSRIs, the next step should be a frank conversation with their prescriber about these alternatives, armed with the specific trial data that supports them. If a psychiatrist is unfamiliar with or unwilling to discuss options like phenelzine or pregabalin, seeking a second opinion from a specialist in anxiety disorders is reasonable and appropriate. The investigational pipeline, including fasedienol and psychedelic-assisted approaches, may eventually offer additional paths forward, but the most underutilized tools are ones that already exist and already have FDA approval or robust clinical evidence behind them.
Frequently Asked Questions
Is phenelzine safe for older adults with social anxiety?
Phenelzine can be used in older adults, but it requires careful monitoring. The tyramine dietary restrictions and drug interaction risks are more concerning in patients who take multiple medications, which is common in older populations. Blood pressure monitoring is essential, and the prescriber needs a complete picture of all other medications, including over-the-counter drugs and supplements.
Can I take a beta-blocker just for public speaking anxiety?
Some people do report benefit from propranolol for isolated performance situations like speeches or presentations, where the primary symptoms are physical, such as trembling or a racing heart. However, the 2024 meta-analysis found no significant benefit over placebo for social anxiety disorder broadly, and all beta-blocker use for anxiety is off-label. It is not a substitute for treatment of generalized social anxiety.
How long does clonazepam take to work for social anxiety?
Clonazepam typically produces noticeable anxiety relief within 30 to 60 minutes of a dose, which is much faster than SSRIs. However, this rapid onset is part of what makes it potentially habit-forming. Long-term studies show sustained improvement over months, but discontinuation should always be gradual and medically supervised.
Are psychedelic therapies available now for social anxiety?
No. As of March 2026, neither psilocybin nor LSD-based therapies are FDA-approved for social anxiety disorder. Clinical trials are underway for related conditions like generalized anxiety disorder and treatment-resistant depression, with anxiety measured as a secondary outcome. New Mexico has established a regulated psilocybin program, but widespread access remains years away.
Can pregabalin be combined with an SSRI?
Yes. Pregabalin has been studied and used as add-on therapy alongside SSRIs and alongside CBT. Because it works through a different mechanism, specifically calcium channel modulation rather than serotonin reuptake, the combination does not carry the same interaction risks as combining two serotonergic medications. However, sedation and dizziness may increase when the two are used together.
You Might Also Like
- OCD Treatment Resistant to SSRIs: The Drug Combination That Breaks Through
- Antibiotic-Resistant Gonorrhea: Why Doctors Are Running Out of Options
- Why Some Functional Medicine Doctors Are Anti-Statin — And Why Cardiologists Push Back
For more, see Alzheimer’s Association — caregiving.
